Related references
Note: Only part of the references are listed.Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients
Wen-Jin Yin et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance
Shunzo Kobayashi
BREAST CANCER (2008)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome
Chafika Mazouni et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry
Katrina R. Bauer et al.
CANCER (2007)
Prognostic markers in triple-negative breast cancer
Emad A. Rakha et al.
CANCER (2007)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
Targeting the DNA repair defect of BRCA tumours
N Turner et al.
CURRENT OPINION IN PHARMACOLOGY (2005)
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
TO Nielsen et al.
CLINICAL CANCER RESEARCH (2004)
The role of BRCA1 in the cellular response to chemotherapy
RD Kennedy et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin
A Bhattacharyya et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
